Verify your evidence before betting $300M.

You're betting $300M on this indication being first-to-file. The decision rests on your team's literature review: months of screening, thousands of abstracts, a comprehensive evidence base supporting the mechanism.

But are you sure?

Publication bias hides negative findings. Competitor unpublished trials sit in registries, not journals. Conference abstracts with secondary endpoint signals don't surface in standard database searches. A single missed study isn't just an oversight—it's discovering mid-Phase II that a competitor already tried this indication and failed, or that someone else filed first.

The first-mover reality: First to file means 3+ years market exclusivity (longer for orphan). Second to file means competing on generic pricing. The difference is $300M vs. $0.

Your team did the work. We make sure nothing slipped through.

The offering

Screening verification

• Independent AI-powered re-screening of your title/abstract decisions
• Gray literature gap analysis: trial registries, conference abstracts, preprints
• Competitor activity check for unpublished or in-progress work
• Report flagging potential missed studies

Full verification

Everything in screening verification, plus:

• Data extraction verification for accuracy and completeness
• Endpoint and outcome extraction cross-check
• Mechanism-of-action evidence validation
• Comprehensive report suitable for investment committee documentation

Why verification matters

First-mover confidence. You're betting the indication on completeness. Verification ensures you're not surprised by a competitor's unpublished trial data or a missed registration that changes the filing landscape.

Gray literature coverage. The best repurposing signals often hide in places your standard search didn't reach: clinical trial registries with unreported outcomes, conference abstracts from niche meetings, failed trials with secondary signals worth pursuing.

Investment protection. A $2,500 verification vs. a $300M indication bet. If we catch even one study that changes your go/no-go decision, the ROI is infinite.

Start with your next repurposing candidate

1. Send us your completed screening or evidence package for your next repurposing candidate.
2. We run independent verification with emphasis on competitive intelligence and gray literature.
3. Your team reviews flagged studies and assesses materiality.
4. Decide with confidence: you've verified the evidence base is complete.

One verification proves the model. Start with the candidate you're most confident about—and verify that confidence holds.